Login to Your Account

Clinic Roundup

Thursday, July 12, 2012

• ImmunoGen Inc., of Waltham, Mass., said it started a Phase I trial of IMGN853, a TAP (Targeted Antibody Payload) compound comprising an FOLR1-targeting antibody attached to cell-killing agent DM4, in patients with ovarian cancer or other solid tumors that overexpress FOLR1, including non-small-cell lung cancer. Once the maximum-tolerated dose is established, the activity of the compound will be evaluated in disease-specific patient cohorts.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription